Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
复制标题
DOI：
10.1186/s12885-021-08277-7
复制
发表时间：
2021-05-11
期刊：
影响因子：
3.8
通讯作者：
Kim YT
中科院分区：
文献类型：
--
作者：
Chun JW;Lee SH;Kim JS;Park N;Huh G;Cho IR;Paik WH;Ryu JK;Kim YT
FOLFIRINOX（FFX）和吉西他滨+nab-紫杉醇（GNP）已被推荐为转移性胰腺癌（mPC）的一线化疗。然而，缺乏证据，不仅比较两种方案，而且比较序贯治疗（FFX-GNP与GnP-FFX）。回顾性收集了528例mPC患者（FFX，n = 371; GNP，n = 157）的数据。倾向评分匹配，以减轻两组的不平衡。分析患者的总生存期（OS）、无进展生存期（PFS）和毒性反应。在整个人群中，匹配前和匹配后，FFX组的OS（12.5个月vs. 10.3个月，P = 0.05）和PFS（7.1个月vs. 5.8个月，P = 0.02）较长（OS：11.8个月vs. 10.3个月，P = 0.02; PFS：7.2个月vs. 5.8个月，P < 0.01）。对于序贯治疗，OS和PFS无显著差异。在GNP组中，由于毒性而中断化疗的频率更高（6.8% vs. 29.3%，P < 0.001），停止化疗与死亡率显著相关（z =-1.94，P = 0.03）。在mPC中，FFX的总生存期长于GNP，但在序贯治疗的比较中则不然。在GNP期间，更频繁的不良事件随后中断治疗可能导致生存结局较差。因此，对于mPC，FFX将是比GNP更好的一线治疗选择。在线版本包含补充材料，可通过10.1186/s12885-021-08277-7获得。
FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC). However, the evidence is lacking comparing not only two regimens, but also sequential treatment (FFX–GnP vs. GnP–FFX). Data of 528 patients (FFX, n = 371; GnP, n = 157) with mPC were collected retrospectively. Propensity score matching was conducted to alleviate imbalance of the two groups. Overall survival (OS), progression free survival (PFS), and toxicity of patients were analyzed. In the whole population, OS (12.5 months vs. 10.3 months, P = 0.05) and PFS (7.1 months vs. 5.8 months, P = 0.02) were longer in the FFX group before matching and after matching (OS: 11.8 months vs. 10.3 months, P = 0.02; PFS: 7.2 months vs. 5.8 months, P < 0.01). For sequential treatment, OS and PFS showed no significant difference. Interruptions of chemotherapy due to toxicities were more frequent (6.8 vs. 29.3%, P < 0.001) in the GnP group, and cessation of chemotherapy showed a significant association with mortality (z = − 1.94, P = 0.03). FFX achieved a longer overall survival than GnP in mPC, but not in the comparison for sequential treatment. More frequent adverse events followed by treatment interruptions during GnP might lead to a poor survival outcome. Therefore, FFX would be a better first-line treatment option than GnP for mPC. The online version contains supplementary material available at 10.1186/s12885-021-08277-7.
登录
查看更多内容
影响因子：
5.8
作者：
Tabernero, Josep;Chiorean, E. Gabriela;Von Hoff, Daniel D.
通讯作者：
Von Hoff, Daniel D.
影响因子：
4
作者：
Cavanna, Luigi;Stroppa, Elisa Maria;Vecchia, Stefano
通讯作者：
Vecchia, Stefano
影响因子：
3
作者：
Cho, In Rae;Kang, Huapyong;Bang, Seungmin
通讯作者：
Bang, Seungmin
DOI：
10.6004/jnccn.2019.5007
发表时间：
2019-05-01
影响因子：
13.4
作者：
Tempero, Margaret A.
通讯作者：
Tempero, Margaret A.
影响因子：
45.3
作者：
Burris, HA;Moore, MJ;VanHoff, DD
通讯作者：
VanHoff, DD